Literature DB >> 20641005

Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.

Sam Gandy1, Adam J Simon, John W Steele, Alex L Lublin, James J Lah, Lary C Walker, Allan I Levey, Grant A Krafft, Efrat Levy, Frédéric Checler, Charles Glabe, Warren B Bilker, Ted Abel, James Schmeidler, Michelle E Ehrlich.   

Abstract

OBJECTIVE: Recent evidence suggests that high molecular weight soluble oligomeric Abeta (oAbeta) assemblies (also known as Abeta-derived diffusible ligands, or ADDLs) may represent a primary neurotoxic basis for cognitive failure in Alzheimer disease (AD). To date, most in vivo studies of oAbeta/ADDLs have involved injection of assemblies purified from the cerebrospinal fluid of human subjects with AD or from the conditioned media of Abeta-secreting cells into experimental animals. We sought to study the bioactivities of endogenously formed oAbeta/ADDLs generated in situ from the physiological processing of human amyloid precursor protein (APP) and presenitin1 (PS1) transgenes.
METHODS: We produced and histologically characterized single transgenic mice overexpressing APP(E693Q) or APP(E693Q) X PS1DeltaE9 bigenic mice. APP(E693Q) mice were studied in the Morris water maze (MWM) task at 6 and 12 months of age. Following the second MWM evaluation, mice were sacrificed, and brains were assayed for Abetatotal, Abeta40, Abeta42, and oAbeta/ADDLs by enzyme-linked immunosorbent assay (ELISA) and were also histologically examined. Based on results from the oAbeta/ADDL ELISA, we assigned individual APP(E693Q) mice to either an undetectable oAbeta/ADDLs group or a readily detectable oAbeta/ADDLs group. A days to criterion (DTC) analysis was used to determine delays in acquisition of the MWM task.
RESULTS: Both single transgenic and bigenic mice developed intraneuronal accumulation of APP/Abeta, although only APP(E693Q) X PS1Delta9 bigenic mice developed amyloid plaques. The APP(E693Q) mice did not develop amyloid plaques at any age studied, up to 30 months. APP(E693Q) mice were tested for spatial learning and memory, and only 12-month-old APP(E693Q) mice with readily detectable oAbeta/ADDLs displayed a significant delay in acquisition of the MWM task when compared to nontransgenic littermates.
INTERPRETATION: These data suggest that cerebral oAbeta/ADDL assemblies generated in brain in situ from human APP transgenes may be associated with cognitive impairment. We propose that a DTC analysis may be a sensitive method for assessing the cognitive impact in mice of endogenously generated oligomeric human Abeta assemblies. ANN NEUROL 2010.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20641005      PMCID: PMC3094694          DOI: 10.1002/ana.22052

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  35 in total

1.  Toxicity of Dutch (E22Q) and Flemish (A21G) mutant amyloid beta proteins to human cerebral microvessel and aortic smooth muscle cells.

Authors:  Z Wang; R Natté; J A Berliner; S G van Duinen; H V Vinters
Journal:  Stroke       Date:  2000-02       Impact factor: 7.914

2.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

Authors:  J Steven Jacobsen; Chi-Cheng Wu; Jeffrey M Redwine; Thomas A Comery; Robert Arias; Mark Bowlby; Robert Martone; John H Morrison; Menelas N Pangalos; Peter H Reinhart; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

3.  Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Authors:  Timothy P O'Leary; Richard E Brown
Journal:  Behav Brain Res       Date:  2009-02-06       Impact factor: 3.332

4.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

5.  Expression of APP in transgenic mice: a comparison of neuron-specific promoters.

Authors:  K Andrä; D Abramowski; M Duke; A Probst; K H Wiederhold; K Bürki; M Goedert; B Sommer; M Staufenbiel
Journal:  Neurobiol Aging       Date:  1996 Mar-Apr       Impact factor: 4.673

6.  Sequencing of the Alzheimer's APP gene Dutch variant (APP-D)

Authors:  R G Vidal; I Fernandez-Madrid; B Frangione; E Levy
Journal:  Hum Mutat       Date:  1993       Impact factor: 4.878

7.  Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function.

Authors:  James P Cleary; Dominic M Walsh; Jacki J Hofmeister; Ganesh M Shankar; Michael A Kuskowski; Dennis J Selkoe; Karen H Ashe
Journal:  Nat Neurosci       Date:  2004-12-19       Impact factor: 24.884

8.  Generation and regulation of beta-amyloid peptide variants by neurons.

Authors:  G K Gouras; H Xu; J N Jovanovic; J D Buxbaum; R Wang; P Greengard; N R Relkin; S Gandy
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

9.  Visuospatial function is a significant contributor to functional status in patients with Alzheimer's disease.

Authors:  Toshiya Fukui; Eiyai Lee
Journal:  Am J Alzheimers Dis Other Demen       Date:  2009-04-29       Impact factor: 2.035

Review 10.  Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease.

Authors:  Alex L Lublin; Sam Gandy
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb
View more
  70 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

2.  Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration.

Authors:  Haim Belinson; Zehavit Kariv-Inbal; Rakez Kayed; Eliezer Masliah; Daniel M Michaelson
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice.

Authors:  Davide Tampellini; Estibaliz Capetillo-Zarate; Magali Dumont; Zhenyong Huang; Fangmin Yu; Michael T Lin; Gunnar K Gouras
Journal:  J Neurosci       Date:  2010-10-27       Impact factor: 6.167

4.  Critical role of intraneuronal Aβ in Alzheimer's disease: technical challenges in studying intracellular Aβ.

Authors:  Gunnar K Gouras; Katarina Willén; Davide Tampellini
Journal:  Life Sci       Date:  2012-06-19       Impact factor: 5.037

5.  Neuronal Store-Operated Calcium Entry and Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer's Disease.

Authors:  Hua Zhang; Lili Wu; Ekaterina Pchitskaya; Olga Zakharova; Takashi Saito; Takaomi Saido; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2015-09-30       Impact factor: 6.167

Review 6.  Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.

Authors:  Daniel W Wesson; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

Review 7.  Aβ oligomer-induced synapse degeneration in Alzheimer's disease.

Authors:  Kyle C Wilcox; Pascale N Lacor; Jason Pitt; William L Klein
Journal:  Cell Mol Neurobiol       Date:  2011-05-03       Impact factor: 5.046

Review 8.  Effect of amyloids on the vesicular machinery: implications for somatic neurotransmission.

Authors:  Anand Kant Das; Rucha Pandit; Sudipta Maiti
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-05       Impact factor: 6.237

9.  Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease.

Authors:  Matthew E Seward; Eric Swanson; Andrés Norambuena; Anja Reimann; J Nicholas Cochran; Rong Li; Erik D Roberson; George S Bloom
Journal:  J Cell Sci       Date:  2013-01-23       Impact factor: 5.285

Review 10.  Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.

Authors:  Sam Gandy; Steven T DeKosky
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.